News

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

David Denton will replace Matthew Friend, who will remain at the company until 4 September to assist with the handover.

Retail traders cited Novo CEO Mike Doustdar’s comment that Novo could afford a $20B, $30B or $40B deal if it was “worth it.”

Earlier this week, Pfizer reported that its Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-squamous non-small cell lung cancer failed to show a statistically significant overall survival benefit over docetaxel in the overall population, while the U.S. FDA approved IBRANCE as a maintenance option for adults with HR-positive, HER2-positive advanced or metastatic breast cancer following induction therapy. Together, the mixed lung cancer data and the expanded IBRANCE...

In the most recent trading session, Pfizer (PFE) closed at $24.04, indicating a -2.75% shift from the previous trading day.

The U.S. Food and Drug Administration approved the use of Ibrance as maintenance treatment for adults with a specific type of advanced or metastatic breast cancer on Wednesday.

AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% a

With an annual dividend yield of 6.96%, Pfizer Inc. (NYSE:PFE) is included among the 12 Best S&P 500 Stocks to Buy for Dividends. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s […]

(Updates with Pfizer's response in the last two paragraphs.) Pfizer (PFE) has been dismissed as a

The sports apparel giant is turning to new financial leadership as it looks to make more progress with its “Win Now” turnaround strategy.

Nike Inc (NYSE:NKE, XETRA:NKE) has announced that David Denton will join the company as executive vice president and chief financial officer effective August 17, succeeding Matthew Friend, who will remain with the company through September 4 to support the transition. According to the...

Lilly's GLP-1 leadership, expanding pipeline and strong earnings growth outlook make it a standout pick over Pfizer despite its premium valuation.

David Denton, who has led Pfizer's finances since 2022, will take over as Nike's chief financial officer on Aug. 17

Nike names David Denton, a former Pfizer and CVS Health executive, as its next chief financial officer, and provides updated guidance.

IBB, Novartis, Pfizer and Eli Lilly's have been highlighted in this Investment Ideas article.

Nike (NYSE:NKE) has appointed David M. Denton as its incoming Chief Financial Officer. Denton, who has held senior finance roles at Pfizer and Lowe's, is set to succeed current CFO Matthew Friend. The transition comes as Nike continues a multiyear turnaround and addresses operational challenges and skepticism about its execution. Nike, a major global sportswear and footwear company, is in the middle of a turnaround that includes operational adjustments and a renewed focus on execution. The...

Nike announced a CFO transition and said fourth-quarter results remain on track, excluding a one-time tariff refund benefit.

David Denton will join Nike Inc. as executive vice president and chief financial officer on Aug. 17, succeeding Matthew Friend.

Don't wait until they recover to initiate positions.

David Denton’s appointment, effective Aug. 17, comes as the company struggles to execute its turnaround.

The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.

Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.

Pfizer Inc. (NYSE:PFE) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 20, 2026, Pfizer Inc. (NYSE:PFE) CEO Albert Bourla said on “In Good Company” that pandemic-era urgency allowed an eight-month COVID vaccine timeline. He said that regulators and governments “reverted to more conservative” approaches afterward. […]

Everyone is still arguing about Novo Nordisk (NYSE:NVO), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy and Ozempic into household names and dragged the entire pharma sector into a multi-year hype cycle. But here’s what you should actually be watching. The reality check has already started, and the numbers are uglier than the headlines ... Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

Pfizer (NYSE:PFE) reported that its late stage lung cancer drug sigvotatug vedotin did not significantly improve overall survival in a pivotal Phase 3 trial. The trial compared sigvotatug vedotin to standard chemotherapy docetaxel in patients with metastatic non squamous non small cell lung cancer. The drug, part of the Seagen portfolio acquired for US$43b, showed a manageable safety profile and encouraging signals in a subset of patients, but the main efficacy goal was not met. For Pfizer,...

PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.

Pfizer shares fell about 1.5% after sigvotatug vedotin failed to significantly improve survival in a late-stage lung cancer trial.

The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.